Navigation Links
Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
Date:12/11/2009

rcent, respectively. Responders in both the FLT3 ITD-positive and FLT3 ITD-negative groups had at least a doubling of median overall survival compared to non-responders (26 vs. nine weeks for FLT3 ITD-positive, and 19 vs. nine weeks for FLT3 ITD-negative. The most common drug-related AEs in the study were gastrointestinal-related (nausea, vomiting, dysgeusia, abdominal pain, anorexia, diarrhea), skin irritation, and peripheral edema. All of these drug-related adverse events occurred in less than 15% of the study population, with most occurring in less than 10% of patients, and were primarily mild to moderate in severity. In addition, some patients experienced QTcF interval prolongation, which was asymptomatic and reversible. The maximum tolerated dose was determined to be 200 mg continuous once-daily dosing.

For more information about the ACE Study, please visit http://www.clinicaltrials.gov/ct2/show/NCT00989261?term=ac220&rank=1, or call 858-334-2136 in the United States, or email to ACEstudy@ambitbio.com.

About AC220

AC220, Ambit's lead product candidate, is a novel, potent, highly selective, orally bioavailable second-generation FLT3 inhibitor currently under evaluation as a monotherapy treatment in adult and elderly patients with relapsed or refractory acute myeloid leukemia (AML). AML is the most common type of blood cancer in adults, and the kinase FLT3 is mutated and constitutively activated in 25-40 percent of such patients. FLT3 ITD mutations predict poor prognosis and decreased response to existing treatments, including chemotherapy and hematopoietic stem cell transplant. Ambit leveraged KINOMEscan(TM), the company's proprietary, high-throughput method for screening small molecule compounds against a large number of human kinases, to advanc
'/>"/>

SOURCE Ambit Biosciences Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT
2. YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES
3. Cell Biosciences Acquires Protein Forest
4. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
5. Dow AgroSciences, Agrisoma Biosciences Announce Research and Commercial License Option Agreement for Agricultural Crops
6. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
7. YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA
8. American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor
9. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
10. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING
11. Regado Biosciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... (1912-1954), is famous for a number of breakthroughs, which ... he published a paper, which laid the foundation of ... computer algorithm. He next played a pivotal role in ... the German military codes, enabling the Allies to defeat ... late 1940,s he turned his attention to artificial intelligence ...
(Date:7/31/2014)... 2014 The SNIS Foundation recognized its ... fund a translational research project.  The first award ... was presented at the Society of NeuroInterventional Surgery ... Colorado Springs, CO. ... neurovascular conditions, SNIS formed the SNIS Foundation, in ...
(Date:7/31/2014)... July 31, 2014 North Shore Towers, a ... partnered with GI Energy, one of the nation’s leading combined ... million upgrade of its 43-year-old CHP system. The original CHP ... an effort to extend the life of the plant, GI ... associated electrical and heat recovery equipment, while maintaining continuous operation ...
(Date:7/31/2014)... Senomyx , Inc. (NASDAQ: SNMX ... technologies to discover, develop, and commercialize novel flavor ... industries, today reported financial results for the second ... with $33.6 million in cash and highly liquid ... Senomyx achieved another important milestone with the regulatory ...
Breaking Biology Technology:A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 2A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 3SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 3North Shore Towers Partners with GI Energy to Install Turnkey Natural Gas-Fired Combined Heat and Power Plant 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16
... Following the,completion of the Phase II clinical development of ... end of Phase,II meeting with the FDA to discuss ... there was an open and highly constructive discussion with ... the first ever formal discussions with the,agency to license ...
... developed at MIT and Boston University, could help prevent ... that have already become resistant. , Researchers from both ... defense systems, enhancing the effectiveness of antibiotics. The work ... the Proceedings of the National Academy of Sciences ...
... LAS VEGAS, March 2 American Pacific Corporation ... announce that its wholly-owned subsidiary AMPAC Fine Chemicals ... Award from the Department of Toxic Substances Control ... of California (CICC). The award recognizes the overall ...
Cached Biology Technology:Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting 2Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting 3MIT, BU team combats antibiotic resistance with engineered viruses 2AMPAC Fine Chemicals Receives the California Pollution Prevention Challenge Award Two Consecutive Years 2AMPAC Fine Chemicals Receives the California Pollution Prevention Challenge Award Two Consecutive Years 3
(Date:8/1/2014)... The co-authors of a new study, including two ... why scientists, industry representatives and policymakers must collaborate ... from shale gas development. Viorel Popescu and Maureen ... SFU,s Biological Sciences department, are among eight international ... Frontiers in Ecology and the Environment . , ...
(Date:7/31/2014)... natural-gas production from shale rock has increased by ... still do not fully understand the industry,s effects ... in the journal Frontiers in Ecology and ... to vastly outpace scientific examination, a team of ... including Princeton University, concluded that determining the environmental ...
(Date:7/31/2014)... to be a key gene responsible for hearing in mammals. ... of the inner ear that contracts and expands rapidly to ... horn, amplify sound waves to make hearing more sensitivity. ... online edition of Molecular Biology and Evolution , Peng ... evolved to play a critical role in the ultrasonic hearing ...
Breaking Biology News(10 mins):Scientists warn time to stop drilling in the dark 2Scientists warn time to stop drilling in the dark 3'Fracking' in the dark: Biological fallout of shale-gas production still largely unknown 2'Fracking' in the dark: Biological fallout of shale-gas production still largely unknown 3
... popular pesticides can decimate amphibian populations when mixed together ... within limits considered safe, according to University of Pittsburgh ... Oecologia . Such "cocktails of contaminants" are frequently ... findings offer the first illustration of how a large ...
... Apparao Rao and his team are researching nano-scale cantilevers that ... chemicals or gases in the air. Put them into a ... chemical alerts in battle, in industry, in health care and ... devices to do this work has been something we,ve only ...
... has become a major venue for presenting cutting-edge ... said meeting chair Steven M. Dubinett, M.D., director ... UCLA Jonsson Comprehensive Cancer Center. "As the only ... it continues to foster important transdisciplinary interactions that ...
Cached Biology News:Pitt research finds that low concentrations of pesticides can become toxic mixture 2Pitt research finds that low concentrations of pesticides can become toxic mixture 3Clemson researchers advance nano-scale electromechanical sensors 2AACR to host Seventh Annual International Conference on Frontiers in Cancer Prevention Research 2
... Kit includes the pZErO-1 vector with Zeocin ... pZErO-1 vector utilizes positive selection to eliminate ... Zeocin resistance gene reduces the overall vector ... The kit contains all of the reagents ...
Request Info...
See product name for description....
... mixture excluding l-[U-14C]methionine, 1.85 MBq, 50 ... sterilized. > 1.85 GBq/mg atom ... Mixture of Ala, Arg, Asp, ... Phe, Pro, Ser, Thr, Tyr and ...
Biology Products: